{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:02:02Z","timestamp":1787320922736,"version":"build-2736575974"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T00:00:00Z","timestamp":1629504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Agence R\u00e9gionale de Sant\u00e9 Hauts de France and Agence Onco Hauts-de-France"},{"name":"AMH dosages"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>STUDY QUESTION<\/jats:title>\n                    <jats:p>What is the influence of age and chemotherapy regimen on the longitudinal blood anti-M\u00fcllerian hormone (AMH) variations in a large series of adolescents and young adult (AYA) (15\u201324\u2009years old) and non-AYA (25\u201335\u2009years old) lymphoma patients?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SUMMARY ANSWER<\/jats:title>\n                    <jats:p>In case of alkylating regimen treatment, there was a deep and sustained follicular depletion in AYA as well as non-AYA patients; however in both groups, the ovarian toxicity was extremely low in cases of non-alkylating treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                    <jats:p>AMH is now well-recognised to be a real-time indicator of ovarian follicular depletion and recovery in women treated by chemotherapy. Its longitudinal variations may discriminate between highly and minimally toxic protocols regarding ovarian function. It has been shown, in different cancer types, that age, type of chemotherapy regimen and pre-treatment AMH levels are the main predictors of ovarian recovery. Large studies on longitudinal AMH variations under chemotherapy in lymphoma patients are few but can provide the opportunity to assess the degree of follicle loss at a young age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                    <jats:p>This prospective cohort study was conducted in the Fertility Observatory of the Lille University Hospital. Data were collected between 2007 and 2016. Non-Hodgkin or Hodgkin lymphoma patients (n\u2009=\u2009122) between 15 and 35\u2009years old were prospectively recruited before commencing chemotherapy. Patients were treated either by a non-alkylating protocol (ABVD group; n\u2009=\u200967) or by an alkylating regimen (alkylating group; n\u2009=\u200955).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                    <jats:p>Serial AMH measurements were performed at baseline (AMH0), 15\u2009days after the start of chemotherapy (AMH1), 15\u2009days before the last chemotherapy cycle (AMH2), and at time 3, 6, 9, 12, 18 and 24\u2009months from the end of chemotherapy. The whole study population was divided into two groups according to age: AYA (15\u201324; n\u2009=\u200965) and non-AYA (25\u201335; n\u2009=\u200957). All patients received a once monthly GnRH agonist injection during the whole treatment period. A linear mixed model was used to account for the repeated measures of single patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                    <jats:p>At baseline, non-AYA patients had higher BMI and lower AMH levels than AYA patients. All AYA and non-AYA patients having received ABVD protocols had regular cycles at 12\u2009months of follow-up. In case of alkylating regimens, amenorrhoea was more frequent in non-AYA patients than in AYA patients at 12\u2009months (37% vs 4%, P\u2009=\u20090.011) and at 24\u2009months (24% vs 4%, P\u2009=\u20090.045). We distinguished a similar depletion phase from AMH0 to AMH2 between ABVD and alkylating groups but significantly different recovery phases from AMH2 to AMH + 24\u2009months. AMH recovery was fast and complete in case of ABVD protocols whatever the age: AMH reached pre-treatment values as soon as the 6th month of follow-up in the AYA group (mean (95% CI) in log AMH M0 vs M6: 3.07 (2.86 to 3.27) vs 3.05 (2.78 to 3.31), P\u2009=\u20091.00) and in the non-AYA group (mean (95% CI) in log AMH M0 vs M6: 2.73 (2.40 to 3.05) vs 2.47 (2.21 to 2.74), P\u2009=\u20091.00). In contrast, no patients from the alkylating group returned to pre-treatment AMH values whatever the age of patients (AYA or non-AYA). Moreover, none of the AMH values post-chemotherapy in the non-AYA group were significantly different from AMH2. Conversely in the AYA group, AMH levels from 6\u2009months (mean (95% CI) in log AMH: 1.79 (1.47 to 2.11), P\u2009&amp;lt;\u20090.001) to 24\u2009months (mean (95% CI) in log AMH: 2.16 (1.80 to 2.52), P \u2264 0.001) were significantly higher than AMH2 (mean (95% CI) in log AMH: 1.13 (0.89 to 1.38)). Considering the whole study population (AYA and non-AYA), pre-treatment AMH levels influenced the pattern of the AMH variation both in alkylating and ABVD protocols (interaction P-value = 0.005 and 0.043, respectively). Likewise, age was significantly associated with the pattern of the recovery phase but only in the alkylating group (interaction P-value =0.001). BMI had no influence on the AMH recovery phase whatever the protocol (interaction P-value = 0.98 in alkylating group, 0.72 in ABVD group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                    <jats:p>There was a large disparity in subtypes of protocols in the alkylating group. The average duration of chemotherapy for patients treated with alkylating protocols was longer than that for patients treated with ABVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                    <jats:p>These results make it possible to develop strategies for fertility preservation according to age and type of protocol in a large series of young lymphoma patients. In addition, it was confirmed that young age does not protect against ovarian damage caused by alkylating agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                    <jats:p>This work was supported by Agence R\u00e9gionale de Sant\u00e9 Hauts de France and Agence Onco Hauts-de-France who provided finances for AMH dosages (n\u00b0 DOS\/SDES\/AR\/FIR\/2019\/282). There are no competing interests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                    <jats:p>DC-2008-642 and CNIL DEC2015-112.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/humrep\/deab189","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T07:12:21Z","timestamp":1627456341000},"page":"2743-2752","source":"Crossref","is-referenced-by-count":25,"title":["Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8232-3959","authenticated-orcid":false,"given":"C","family":"Decanter","sequence":"first","affiliation":[{"name":"Academic ART and Fertility Preservation Centre, Jeanne de Flandre Hospital, Lille University Hospital, Lille, France"},{"name":"EA 4308 Gam\u00e9tog\u00e9n\u00e8se et qualit\u00e9 du gam\u00e8te, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Delepine","sequence":"additional","affiliation":[{"name":"Academic ART and Fertility Preservation Centre, Jeanne de Flandre Hospital, Lille University Hospital, Lille, France"},{"name":"EA 4308 Gam\u00e9tog\u00e9n\u00e8se et qualit\u00e9 du gam\u00e8te, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Behal","sequence":"additional","affiliation":[{"name":"Department of Biostatistics of the Lille University Hospital, ULR 2694-METRICS: Health Technologies Evaluation and Medical Practices, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Manier","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Bruno","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology Jeanne de Flandre Hospital, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Barbatti","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology Jeanne de Flandre Hospital, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Robin","sequence":"additional","affiliation":[{"name":"Academic ART and Fertility Preservation Centre, Jeanne de Flandre Hospital, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Labreuche","sequence":"additional","affiliation":[{"name":"Department of Biostatistics of the Lille University Hospital, ULR 2694-METRICS: Health Technologies Evaluation and Medical Practices, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"Department of Hematology, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Pigny","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Hormonology, Metabolism, Nutrition and Oncology, Lille University Hospital, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,21]]},"reference":[{"key":"2021092008511534100_deab189-B2","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021092008511534100_deab189-B3","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/humrep\/del201","article-title":"The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer","volume":"21","author":"Anderson","year":"2006","journal-title":"Hum Reprod"},{"key":"2021092008511534100_deab189-B4","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","article-title":"Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group","volume":"23","author":"Behringer","year":"2005","journal-title":"JCO"},{"key":"2021092008511534100_deab189-B5","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"JCO"},{"key":"2021092008511534100_deab189-B6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1210\/jc.2011-3180","article-title":"Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study","volume":"97","author":"Brougham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2021092008511534100_deab189-B7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1210\/jc.2018-02257","article-title":"Differential rates of change in measures of ovarian reserve in young cancer survivors across the reproductive lifespan","volume":"104","author":"Cameron","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2021092008511534100_deab189-B8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.rbmo.2009.11.010","article-title":"Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results","volume":"20","author":"Decanter","year":"2010","journal-title":"Reprod Biomed Online"},{"key":"2021092008511534100_deab189-B9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.fertnstert.2014.05.014","article-title":"Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimullerian hormone assay","volume":"102","author":"Decanter","year":"2014","journal-title":"Fertil Steril"},{"key":"2021092008511534100_deab189-B10","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/humrep\/deaa193","article-title":"Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study","volume":"35","author":"Delattre","year":"2020","journal-title":"Hum Reprod"},{"key":"2021092008511534100_deab189-B11","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","article-title":"No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial","volume":"34","author":"Demeestere","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021092008511534100_deab189-B12","first-page":"3593","article-title":"Does AMH Relate to Timing of Menopause? Results of an Individual Patient Data Meta-Analysis","volume":"103","author":"Depmann","year":"2018"},{"key":"2021092008511534100_deab189-B13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/humupd\/dmt062","article-title":"The physiology and clinical utility of anti-Mullerian hormone in women","volume":"20","author":"Dewailly","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2021092008511534100_deab189-B14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2017.03.035","article-title":"Prospective evaluation of serum anti-Mullerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer","volume":"79","author":"Dezellus","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021092008511534100_deab189-B15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.fertnstert.2012.09.039","article-title":"Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy","volume":"99","author":"Dillon","year":"2013","journal-title":"Fertil Steril"},{"key":"2021092008511534100_deab189-B16","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2020.08.011","article-title":"Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons","volume":"114","author":"Dolmans","year":"2020","journal-title":"Fertil Steril"},{"key":"2021092008511534100_deab189-B17","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.fertnstert.2021.03.008","article-title":"Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers","volume":"115","author":"Dolmans","year":"2021","journal-title":"Fertil Steril"},{"key":"2021092008511534100_deab189-B44","article-title":"ESHRE guideline: female fertility preservation","volume":"14","year":"2020","journal-title":"Human Reprod Open"},{"key":"2021092008511534100_deab189-B18","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1210\/clinem\/dgz283","article-title":"Antimullerian hormone and impending menopause in late reproductive age: the Study of Women's Health Across the Nation","volume":"105","author":"Finkelstein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2021092008511534100_deab189-B19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/pbc.24967","article-title":"The Twelfth International Conference on the long-term complications of treatment of children and adolescents with cancer","volume":"61","author":"Green","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"2021092008511534100_deab189-B20","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jpag.2016.04.009","article-title":"Anti-mullerian hormone in female adolescent cancer patients before, during, and after completion of therapy: a pilot feasibility study","volume":"29","author":"Gupta","year":"2016","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"2021092008511534100_deab189-B21","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.fertnstert.2012.08.008","article-title":"Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study","volume":"98","author":"Hagen","year":"2012","journal-title":"Fertil Steril"},{"key":"2021092008511534100_deab189-B22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.fertnstert.2010.04.006","article-title":"Correlation of ovarian reserve tests with histologically determined primordial follicle number","volume":"95","author":"Hansen","year":"2011","journal-title":"Fertil Steril"},{"key":"2021092008511534100_deab189-B23","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3324\/haematol.2011.045856","article-title":"Management of fertility in patients treated for Hodgkin's lymphoma","volume":"96","author":"Harel","year":"2011","journal-title":"Haematologica"},{"key":"2021092008511534100_deab189-B24","doi-asserted-by":"crossref","first-page":"185ra162","DOI":"10.1126\/scitranslmed.3005402","article-title":"Cyclophosphamide triggers follicle activation and \"burnout\"; AS101 prevents follicle loss and preserves fertility","volume":"5","author":"Kalich-Philosoph","year":"2013","journal-title":"Sci Transl Med"},{"key":"2021092008511534100_deab189-B25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/molehr\/gar059","article-title":"Data-driven assessment of the human ovarian reserve","volume":"18","author":"Kelsey","year":"2012","journal-title":"Mol Hum Reprod"},{"key":"2021092008511534100_deab189-B26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1055\/s-0033-1349854","article-title":"The progressive reduction in the ovarian reserve in young women after anticancer treatment","volume":"45","author":"Krawczuk-Rybak","year":"2013","journal-title":"Horm Metab Res"},{"key":"2021092008511534100_deab189-B27","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00520-017-3597-8","article-title":"The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options","volume":"25","author":"Lewin","year":"2017","journal-title":"Support Care Cancer"},{"key":"2021092008511534100_deab189-B28","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/humrep\/dem027","article-title":"Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury","volume":"22","author":"Meirow","year":"2007","journal-title":"Hum Reprod"},{"key":"2021092008511534100_deab189-B29","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/cncr.22199","article-title":"Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate","volume":"107","author":"Meirow","year":"2006","journal-title":"Cancer"},{"key":"2021092008511534100_deab189-B30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/humupd\/dms022","article-title":"How do chemotherapeutic agents damage the ovary?","volume":"18","author":"Morgan","year":"2012","journal-title":"Hum Reprod Update"},{"key":"2021092008511534100_deab189-B31","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/pbc.24327","article-title":"Acute onset of ovarian dysfunction in young females after start of cancer treatment","volume":"60","author":"Morse","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2021092008511534100_deab189-B32","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S1470-2045(20)30594-5","article-title":"Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"},{"key":"2021092008511534100_deab189-B33","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.maturitas.2015.06.026","article-title":"Anti-mullerian hormone (AMH) is associated with natural menopause in a population-based sample: the CARDIA Women's Study","volume":"81","author":"Nair","year":"2015","journal-title":"Maturitas"},{"key":"2021092008511534100_deab189-B34","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline Update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021092008511534100_deab189-B35","doi-asserted-by":"crossref","first-page":"10159","DOI":"10.1158\/0008-5472.CAN-07-2042","article-title":"A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve","volume":"67","author":"Oktem","year":"2007","journal-title":"Cancer Res"},{"key":"2021092008511534100_deab189-B36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7827-12-26","article-title":"Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review","volume":"12","author":"Peigne","year":"2014","journal-title":"Reprod Biol Endocrinol"},{"key":"2021092008511534100_deab189-B37","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/nm1197-1228","article-title":"Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction","volume":"3","author":"Perez","year":"1997","journal-title":"Nat Med"},{"key":"2021092008511534100_deab189-B38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.fertnstert.2020.03.037","article-title":"Evaluation of ovarian tissue transplantation: results from three clinical centers","volume":"114","author":"Shapira","year":"2020","journal-title":"Fertil Steril"},{"key":"2021092008511534100_deab189-1001","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"key":"2021092008511534100_deab189-B39","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1001\/jama.2017.14588","article-title":"Association between biomarkers of ovarian reserve and infertility among older women of reproductive age","volume":"318","author":"Steiner","year":"2017","journal-title":"JAMA"},{"key":"2021092008511534100_deab189-B40","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1210\/clinem\/dgaa172","article-title":"Modeling variation in the reproductive lifespan of female adolescent and young adult cancer survivors using AMH","volume":"105","author":"Su","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2021092008511534100_deab189-B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju207","article-title":"Risk of premature menopause after treatment for Hodgkin's lymphoma","volume":"106","author":"Swerdlow","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021092008511534100_deab189-B42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2011.37.1989","article-title":"Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study","volume":"30","author":"van der Kaaij","year":"2012","journal-title":"JCO"},{"key":"2021092008511534100_deab189-B43","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.2017.76.3441","article-title":"Reproductive function and outcomes in female survivors of childhood, adolescent, and young adult cancer: a review","volume":"36","author":"van Dorp","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/10\/2743\/40409263\/deab189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/10\/2743\/40409263\/deab189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T04:52:44Z","timestamp":1632113564000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/10\/2743\/6356123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,21]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,8,21]]},"published-print":{"date-parts":[[2021,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab189","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,8,21]]}}}